The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
Belite Bio announced preliminary Q4 2025 results and plans to submit an NDA for tinlarebant in Q2 2026 following positive Phase 3 trial results. BioArctic reported record financial results with operating profit exceeding SEK 1.2 billion for 2025. Recordati delivered strong preliminary full-year 2025 results despite FX headwinds.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07450222 |
Implementation of Effective Hypertension Management Approaches: OSF HealthCare |
ENROLLING_BY_INVITATION | |
| NCT07358858 |
A Food Effect Study of QLS1410 in Healthy Chinese Adults |
NOT_YET_RECRUITING | PHASE1 |
| NCT07152444 |
A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension |
NOT_YET_RECRUITING | PHASE1 |
| NCT07142356 |
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension |
RECRUITING | PHASE2 |
| NCT07090161 |
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension |
RECRUITING | PHASE2 |
| NCT07061054 |
Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN System |
NOT_YET_RECRUITING | NA |
| NCT07051603 |
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population |
RECRUITING | PHASE1 |
| NCT07049289 |
Telemonitoring in Arterial Hypertension |
ACTIVE_NOT_RECRUITING | NA |
| NCT07031739 |
Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity |
RECRUITING | NA |
| NCT07005050 |
Renal Pelvic Denervation Pilot Trial |
RECRUITING | NA |
